Tag: Algernon Pharmaceuticals - Page 2 - Psychedelic Alpha

Read more about the article Algernon NeuroScience Announces Successful Dosing of 2nd Cohort in Phase 1 DMT Clinical Study

Algernon NeuroScience Announces Successful Dosing of 2nd Cohort in Phase 1 DMT Clinical Study

Post published:April 4, 2023
Post category:Press Release

Read more about the article Algernon NeuroScience Announces U.S. SEC Qualification of Regulation A+ Tier II Offering to Raise up to USD $10M

Algernon NeuroScience Announces U.S. SEC Qualification of Regulation A+ Tier II Offering to Raise up to USD $10M

Post published:April 3, 2023
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Announces Launch of Rights Offering

Algernon Pharmaceuticals Announces Launch of Rights Offering

Post published:March 21, 2023
Post category:Press Release

Read more about the article Algernon NeuroScience Appoints Global TBI Expert and Former NFL Neurological Player Care Safety Director Dr. David Brody to Advisory Board

Algernon NeuroScience Appoints Global TBI Expert and Former NFL Neurological Player Care Safety Director Dr. David Brody to Advisory Board

Post published:March 2, 2023
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Announces 4 for 1 Forward Share Split

Algernon Pharmaceuticals Announces 4 for 1 Forward Share Split

Post published:March 1, 2023
Post category:Press Release

Read more about the article Algernon NeuroScience Initiates Traumatic Brain Injury Research Program With DMT; Appoints Global TBI Expert as Advisor

Algernon NeuroScience Initiates Traumatic Brain Injury Research Program With DMT; Appoints Global TBI Expert as Advisor

Post published:February 21, 2023
Post category:Press Release

Read more about the article Algernon NeuroScience Provides Update on Phase 1 DMT Clinical Study, Drug Found Safe to Proceed to Next Phase

Algernon NeuroScience Provides Update on Phase 1 DMT Clinical Study, Drug Found Safe to Proceed to Next Phase

Post published:February 16, 2023
Post category:Press Release

Read more about the article Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study

Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study

Post published:January 17, 2023
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board

Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board

Post published:January 15, 2023
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Forms Private Subsidiary to Advance Company’s Psychedelic DMT Stroke Program; Files Form 1-A Offering Statement with U.S. SEC for Regulation A+ Offering

Algernon Pharmaceuticals Forms Private Subsidiary to Advance Company’s Psychedelic DMT Stroke Program; Files Form 1-A Offering Statement with U.S. SEC for Regulation A+ Offering

Post published:January 3, 2023
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.